Customized nanotechnology based treatment of Oral Cancer

基于纳米技术的口腔癌定制治疗

• 批准号: 8713626
• 负责人: KuanJu Chen
• 金额: $ 22.07万
• 依托单位: PRIVO TECHNOLOGIES, LLC
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8713626
• 关键词: Address; Adverse effects; American Cancer Society; Animals; Applications Grants; Architecture; Area; Back; Biological Availability; Biotechnology; Bolus Infusion; Cancer Patient; Canis familiaris; Cessation of life; Charge; Chemistry; Chitosan; Chronic Disease; Cisplatin; Clinic; Collaborations; Data; Development; Diffusion; Distant; Dose; Drug Controls; Drug Delivery Systems; Drug Formulations; Early Diagnosis; Encapsulated; Entrepreneurship; FDA approved; Figs - dietary; Foundations; Funding; Future; Goals; Hamsters; Hand; Health Care Costs; Home environment; Hour; In Vitro; Injection of therapeutic agent; Institutes; Intravenous; Investigation; Kidney; Kinetics; Lesion; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of pharynx; Masks; Membrane; Modeling; Monitor; Morbidity - disease rate; Mus; Nanotechnology; Neoplasm Metastasis; Oral; Organ; Paper; Particle Size; Patients; Persons; Pharmaceutical Preparations; Phase; Plasticizers; Platinum; Polymers; Premalignant; Privacy; Property; Provider; Research; Safety; Severities; Staging; Surface; Survival Rate; System; Taste Buds; Taste Perception; Techniques; Technology; Therapeutic; Tissue Model; Tissues; Toxic effect; Travel; Treatment Efficacy; base; cancer site; cancer surgery; cancer therapy; chemotherapy; compliance behavior; controlled release; cost; design; drug efficacy; efficacy evaluation; experience; improved; in vivo; innovation; killings; malignant mouth neoplasm; mortality; nano; nanodrug; nanoencapsulated; nanoengineering; nanoparticle; novel; oncology; preclinical study; prevent; public health relevance; skills; success; tumor

DESCRIPTION (provided by applicant): According to the Oral Cancer (OC) Foundation, oral and pharyngeal cancer will cause 8,000 deaths this year, killing roughly one person per hour. Currently, cisplatin (CIS) is at the forefront of platinum- based chemotherapeutics for treating OC. However, its efficacy is often hindered by its significant systemic toxicity as a result of traditional bolus systemic intravenous (IV) doses. In this proposal, Privo's specific aims focus on developing and optimizing an effective and safe nano engineered drug delivery platform, i.e., chemo-wafer (CW) that reformulates a known anticancer chemotherapy agent ( e.g. cisplatin) for the local and topical treatment of OC, thus replacing injection, increasing the drug's efficacy and significantly reducing its systemic toxicity. The CW platform contains FDA approved chemotherapy drugs and generally recognized as safe (GRAS) materials. It utilizes nano-encapsulation techniques to incorporate drugs into NPs with a controlled-release design that releases chemo drugs at fully tunable and pre-determined rates. The design has the potential to deliver a highly concentrated amount of chemotherapy agents directly to the cancer tissue while minimizing toxic side effects to the surrounding healthy tissues. Part of the project is the development of a novel bilayered vehicle, CW, consisting of a NP front end and a plasticized, non-porous, non-permeable back end. It consists of a mucoadhesive material with unidirection delivery of the drug, which prevents the chemo agent from reaching the taste buds. This addresses the unpleasant taste issues, and increases patient compliance. This project can change the chemotherapy treatment of OC patients by replacing IV delivery with topical delivery of CW, significantly reducing the overall cost of OC treatment. The American Cancer Society has emphasized that oral chemotherapy is truly the wave of the future for oral cancer treatments because it offers patients distinct advantages over traditional IV. The 5- year survival of patient with OC has not significantly improved over the past several decades. Moreover, the survival rate for early detection is significantly higher than later stages (80-90% vs. 25- 35%). Therefore, for patients with pre-malignant to non-metastasized malignant OC, this reformulated nano-encapsulated CW delivery platform has the opportunity to considerably reduce the morbidity and mortality rate of this devastating cancer. The CW has the potential to be administered by the patient and in the privacy of their own homes, avoiding the inconvenience of travel to and from chemotherapy clinics and reducing healthcare cost. The ultimate objectives of Privo Technologies are to develop and commercialize an effective, safe and convenient chemotherapy treatment accessible to many OC patients.

描述（由申请人提供）：根据口腔癌（OC）基金会，口腔和咽癌今年将造成8,000人死亡，每小时大约造成一人死亡。目前，顺铂（CIS）是用于治疗OC的基于铂的化学治疗剂的最前沿。然而，由于传统的全身静脉注射（IV）剂量，由于其严重的全身毒性而阻碍了其功效。在此提案中，Privo的具体目的专注于 开发和优化有效且安全的纳米工程药物输送平台，即化学抗化（CW），该平台将已知的抗癌化学疗法剂（例如顺铂）重新定义，以替代OC的局部和局部治疗 并大大降低其全身毒性。 CW平台包含FDA批准的化学疗法药物，通常被认为是安全（GRAS）材料。它利用纳米封装技术将药物纳入NP，并具有控制性释放的设计，该设计以完全可调和预定的速率释放化学药物。该设计有可能将高度浓度的化学疗法直接传递到癌症组织，同时最大程度地减少对周围健康组织的毒性副作用。该项目的一部分是开发新型双层车辆CW，该车辆由NP前端组成，并具有塑料，非孔，不可渗透的后端。它由粘膜粘附材料组成，并在该药物的单向递送中递送，该材料可防止化学剂达到味蕾。这解决了令人不愉快的口味问题，并提高了患者的依从性。该项目可以通过用局部递送CW替换静脉输送来改变OC患者的化学疗法治疗，从而大大降低了OC治疗的总体成本。美国癌症协会强调，口服化疗确实是口腔癌治疗的未来浪潮，因为它比传统静脉注射患者具有明显的优势。在过去的几十年中，OC患者的5年生存期并未显着改善。此外，早期检测的生存率显着高于后期（80-90％比25-35％）。所以， 对于对非临时性恶性OC的恶性患者，此重新封闭的CW递送平台有机会大大降低这种毁灭性癌症的发病率和死亡率。 CW有可能由患者和自己的房屋隐私管理，避免了往返化疗诊所的不便，并降低了医疗保健费用。 Privo技术的最终目标是开发和商业化许多OC患者可以使用的有效，安全和方便的化学疗法治疗。